Skip to main content

Table 2 Effects of 4- and 12-week treatment of pitavastatin (PTV) and atorvastatin (ATV) on lipid profiles, systemic biomarkers and endothelial progenitor cells

From: Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study

 

Baseline

4 weeks

12 weeks

PTV#

ATV#

 

PTV

ATV

P-value

PTV

ATV

P-value

PTV

ATV

P-value

P-value

P-value

WBC (/cumm)

6223 ± 1790

7184 ± 1563

0.16

6784 ± 2106

7238 ± 1180

0.50

6338 ± 1809

6930 ± 1245

0.34

0.73

0.82

Glucose (mmol/L)

6.98 ± 1.39

6.28 ± 1.04

0.16

7.12 ± 1.71

6.54 ± 1.23

0.39

7.58 ± 2.54

6.54 ± 1.05

0.18

0.71

0.80

HOMA-IR

1.9 ± 1.2

2.0 ± 1.0

0.78

   

5.2 ± 4.8

3.9 ± 2.8

0.41

0.05

<0.05

hs-CRP (mg/dL)

0.18 ± 0.18

0.35 ± 0.37

0.16

0.17 ± 0.11

0.16 ± 0.19

0.90

0.20 ± 0.20

0.17 ± 0.20

0.88

0.93

0.17

TC (mmol/L)

5.20 ± 0.69

5.24 ± 0.64

0.89

3.73 ± 0.53

3.62 ± 0.36

0.53

3.65 ± 0.52

3.56 ± 0.37

0.58

<0.05

<0.05

TG (mmol/L)

1.53 ± 0.71

1.72 ± 0.59

0.46

1.25 ± 0.58

1.26 ± 0.28

0.94

1.15 ± 0.51

1.22 ± 0.39

0.72

0.26

<0.05

LDL-c (mmol/L)

3.70 ± 0.55

3.82 ± 0.85

0.68

2.12 ± 0.46

2.19 ± 0.45

0.68

2.14 ± 0.33

2.09 ± 0.51

0.76

<0.05

<0.05

HDL-c (mmol/L)

1.25 ± 0.25

1.18 ± 0.19

0.38

1.29 ± 0.33

1.18 ± 0.18

0.32

1.25 ± 0.28

1.19 ± 0.20

0.58

0.92

0.96

NOx (μmol/L)

70.8 ± 42.5

78.5 ± 96.8

0.80

75.3 ± 66.1

80.6 ± 62.9

0.85

79.5 ± 86.1

68.9 ± 46.4

0.71

0.95

0.91

IL-10 (pg/ml)

1.8 ± 1.2

1.5 ± 0.8

0.48

2.1 ± 1.6

2.1 ± 1.4

0.91

2.07 ± 1.6

1.7 ± 1.8

0.57

0.87

0.55

TNF-α (pg/ml)

3.6 ± 1.7

4.0 ± 2.8

0.67

3.3 ± 1.8

4.5 ± 2.8

0.22

2.8 ± 0.8

4.3 ± 3.2

0.12

0.45

0.91

ADMA (μmol/L)

0.61 ± 0.10

0.68 ± 0.10

0.09

   

0.56 ± 0.12

0.53 ± 0.12

0.55

0.25

<0.05

SDF-1α (pg/ml)

2619.9 ± 640.5

2851.4 ± 669.1

0.38

2673.5 ± 774.6

3043.3 ± 733.5

0.24

2603.6 ± 757.1

3085.5 ± 701.1

0.16

0.98

0.668

VEGF (pg/ml)

74.33 ± 32.26

69.86 ± 31.53

0.72

118.36 ± 50.05

67.65 ± 42.85

0.01

98.65 ± 46.64

74.04 ± 29.33

0.12

<0.05

0.898

EPC level (%)

           

CD34+KDR+

0.021 ± 0.015

0.039 ± 0.039

0.16

0.035 ± 0.031

0.029 ± 0.024

0.59

0.054 ± 0.044

0.043 ± 0.029

0.45

<0.05

0.57

  1. Values are mean ± standard deviation. #: Difference between baseline, 4 weeks and 12 weeks of treatment in the same group. WBC: white blood cell; HOMA-IR: Homeostasis model of assessment-insulin resistance; TC: total cholesterol; TG: Triglyceride; LDL-c: low-density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; hs-CRP: high sensitivity C-reactive protein; NOx: total nitric oxide; IL-10: interleukin-10; TNF-α: tumor necrosis factor-α; ADMA: asymmetric dimethylarginine; SDF-1α: stromal cell-derived factor-1α; VEGF: vascular endothelial growth factor; EPC: endothelial progenitor cell.